These variations may explain differences observed in the characteristics of new users of GLP-1 RAs across provinces; they were, on average, younger and more likely to have a shorter duration of diabetes and no prior use of antidiabetic medications in all provinces except Quebec, compared to users of SGLT-2i and DPP-4i. The gene discussed is GLP1R; the disease is diabetes mellitus.